Bryce Point Capital LLC Takes Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Bryce Point Capital LLC purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 26,083 shares of the company’s stock, valued at approximately $304,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Franklin Resources Inc. grew its position in shares of Intellia Therapeutics by 10.3% in the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Intellia Therapeutics by 14.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company’s stock worth $157,000 after buying an additional 1,582 shares during the last quarter. Arizona State Retirement System increased its stake in Intellia Therapeutics by 6.1% during the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock worth $327,000 after buying an additional 1,615 shares in the last quarter. E Fund Management Co. Ltd. raised its holdings in shares of Intellia Therapeutics by 10.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company’s stock valued at $210,000 after acquiring an additional 1,634 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Intellia Therapeutics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company’s stock valued at $252,000 after acquiring an additional 2,059 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Oppenheimer dropped their price target on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Wells Fargo & Company dropped their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, February 28th. HC Wainwright began coverage on shares of Intellia Therapeutics in a research note on Wednesday, March 5th. They issued a “buy” rating and a $30.00 price target on the stock. BMO Capital Markets dropped their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, January 10th. Finally, Barclays decreased their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Stock Down 3.8 %

Shares of NASDAQ NTLA opened at $6.63 on Friday. The business’s 50 day moving average is $9.61 and its two-hundred day moving average is $13.33. Intellia Therapeutics, Inc. has a 52-week low of $6.43 and a 52-week high of $28.18. The firm has a market cap of $686.32 million, a price-to-earnings ratio of -1.22 and a beta of 2.23.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.